Find information regarding COVID-19 as it relates to Bechet's Disease.
Every household in the U.S. is eligible to order free at-home COVID-19 tests starting on January 18, 2021. You can only order one package of four rapid tests per household. You will need to provide the following information:
Order your FREE at-home tests from the USPS here.
NOTE: Your order cannot use a place of business address.
Get tested and stay safe!
Learn more about COVID-19 vaccines and approval in the United States here.
Find information on the COVID-19 Vaccine and Equity Project here.
Other accessible and easy to understand resources can be found at COVID Straight Talk.
People with COVID-19 have had a wide range of symptoms reported – ranging from mild symptoms to severe illness. Symptoms may appear 2-14 days after exposure to the virus.
People with these symptoms or a combination of symptoms may have COVID-19:
Or at least two of these symptoms:
Children may have similar symptoms to adults and generally have mild illness. If you have pets, see the CDC's page on COVID and pets or COVID-19 and Animals Frequently Asked Questions.
This list is not all inclusive. Please consult your medical provider for any other symptoms that are severe or concerning you.
Based on CDC guidelines and what we know now, those at high-risk for severe illness from COVID-19 are:
People of all ages with underlying medical conditions, particularly if not well controlled, including:
The American College of Rheumatology (ACR) has developed clinical guidance for the care of adult patients with rheumatic diseases, including Behcet's Disease, during the COVID-19 pandemic. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve. Given the low level of available evidence and the rapidly evolving literature, future updates will follow. Information directly from the ACR is available at COVID-19 Clinical Guidance for Adult Patients with Rheumatic Diseases.
ACR abstract and free access to recommendations for clinicians treating rheumatic patients with of COVID-19 can be accessed here. The CDC recommends patients continue medications and not change their treatment plan without consulting with their healthcare provider.
The best way to prevent illness is to avoid being exposed to the virus. The virus is thought to spread mainly from person-to-person.
Learn more about COVID vaccine access, safety, and history at these links:
The FDA issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
Additional clinical management includes infection prevention and control measures and supportive care, including supplemental oxygen and mechanical ventilatory support when indicated.
The National Institutes of Health have published interim guidelines for the medical management of COVID-19external icon prepared by the COVID-19 Treatment Guidelines Panel. People seeking information about registered clinical trials for COVID-19 in the United States can search for information at ClinicalTrials.gov.